文献速递抗栓抗凝管理

药师主导的VKA转DOAC适用性评估与转换实践

Evaluating direct oral anticoagulant candidacy and pharmacist-led conversion of eligible patients on vitamin K antagonist to direct oral anticoagulants.
PubMed 文献 · Am J Health Syst Pharm · 2026-01-01

该多中心前瞻性研究在约翰霍普金斯两家医院抗凝门诊筛选VKA患者中DOAC适用者,并由药师主导治疗转换。193例合格患者中44例(22.8%)成功转换,104例(53.9%)拒绝,拒绝原因主要为偏好VKA(55例)和费用(49例)。研究为药师主导的年度VKA转DOAC提供了框架。

要点

  • 抗凝门诊中大量VKA患者符合DOAC转换条件。
  • 药师主导的转换流程可行,但患者接受率有限。
  • 拒绝转换的主要原因为偏好VKA和费用问题。

核心结论

  • 两家抗凝门诊多数患者仍使用VKA,但很大比例符合DOAC转换条件。
  • 药师主导的VKA转DOAC框架可行,可每年开展。

研究设计与样本

  • 多中心前瞻性研究,于2024年7月至2025年7月在约翰霍普金斯医院和约翰霍普金斯湾景医疗中心抗凝门诊开展。
  • 第一阶段用同行评议的DOAC转换算法筛选适用者,第二阶段对合格患者进行前瞻性转换并记录拒绝原因。

主要发现

  • 共496例患者就诊,193例合格患者纳入研究。
  • 69例(35.8%)同意转换,104例(53.9%)拒绝,10例(5.2%)失访,10例(5.2%)等待与抗凝门诊医生讨论转换。
  • 44例(22.8%)成功从VKA转换为DOAC。
  • 拒绝转换者中55例报告偏好VKA治疗,49例将费用列为拒绝原因。

临床怎么用

  • 可在抗凝门诊采用同行评议的DOAC转换算法每年筛查VKA适用患者。
  • 药师可主导合格患者的VKA转DOAC治疗转换。
  • 转换前应评估患者偏好和费用障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Since the initial approval of direct oral anticoagulants (DOACs), multiple studies have concluded that DOACs were either noninferior or superior to vitamin K antagonist (VKA) for treatment of venous thromboembolism and prevention of cardioembolic stroke with less incidence of bleeding. Therefore, the objectives of this study were to identify eligible patients on VKA, conduct pharmacist-led therapeutic interchange from VKA to DOACs, and identify reasons for declining conversion. METHODS: This multicenter, prospective study was conducted at anticoagulation clinics at the Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center between July 2024 and July 2025. The first phase focused on screening for DOAC candidacy using a peer-reviewed DOAC conversion algorithm. The second phase consisted of prospective conversion of eligible patients from VKA to a DOAC. If patients declined conversion, the reason they declined was documented. RESULTS: A total of 496 patients were seen in the anticoagulation clinics of the Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center at the time of enrollment. Of the 193 eligible patients who were included in the study, 69 (35.8%) patients agreed to conversion, 104 (53.9%) declined conversion, 10 (5.2%) were lost to follow-up, and 10 (5.2%) were waiting to discuss conversion with their anticoagulation clinic provider. A total of 44 (22.8%) patients were successfully converted from VKA to a DOAC. Of the patients who declined conversion, 55 reported a preference for VKA therapy and 49 identified cost as a reason for declining conversion. CONCLUSION: Although most patients in both anticoagulation clinics remained on VKA therapy, a large proportion of patients were eligible to convert to DOACs. This study provides a framework for pharmacist-led VKA to DOAC conversions, which can be conducted on an annual basis.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Tran BB, Streiff MB. Evaluating direct oral anticoagulant candidacy and pharmacist-led conversion of eligible patients on vitamin K antagonist to direct oral anticoagulants. Am J Health Syst Pharm. 2026. PMID: 41616080. doi:10.1093/ajhp/zxag009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。